KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) EBITDA Margin (2018 - 2025)

Adaptive Biotechnologies' EBITDA Margin history spans 8 years, with the latest figure at 17.82% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 6566.0% year-over-year to 17.82%; the TTM value through Dec 2025 reached 20.62%, up 241.0%, while the annual FY2025 figure was 5.48%, 2852.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 17.82% at Adaptive Biotechnologies, down from 10.95% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 172.3% in Q4 2023 and bottomed at 322.32% in Q2 2023.
  • The 5-year median for EBITDA Margin is 86.83% (2023), against an average of 75.92%.
  • The largest annual shift saw EBITDA Margin tumbled -20207bps in 2023 before it skyrocketed 35525bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 162.39% in 2021, then soared by 56bps to 70.99% in 2022, then surged by 343bps to 172.3% in 2023, then plummeted by -72bps to 47.84% in 2024, then tumbled by -137bps to 17.82% in 2025.
  • Per Business Quant, the three most recent readings for ADPT's EBITDA Margin are 17.82% (Q4 2025), 10.95% (Q3 2025), and 42.52% (Q2 2025).